Table 3. Proportion of patients with clinical improvement from baseline .
**P-values were obtained by using ANCOVA.
mITT = modified intent-to-treat; PP = protocol population; EOT = end of treatment; ANCOVA = analysis of covariance
| Visit | Molnupiravir (N = 608), n (%) | Standard of care (N = 610), n (%) | Proportional difference (95% confidence interval) | Molnupiravir versus standard of care (p-value**) | Molnupiravir (N = 593), n (%) | Standard of care (N = 581), n (%) | Proportional difference (95% confidence interval) | Molnupiravir versus standard of care (p-value**) |
| mITT population | PP population | |||||||
| Day 5 (EOT) | 491 (80.76) | 196 (32.13) | -48.6 (-53.5, -43.8) | <0.0001 | 489 (82.46) | 194 (33.39) | -49.1 (-54.0, -44.2) | <0.0001 |
| Day 10 | 581 (95.56) | 453 (74.26) | -21.3 (-25.1, -17.5) | <0.0001 | 574 (96.80) | 445 (76.59) | -20.4 (-24.1, -16.7) | <0.0001 |
| Day 14 | 592 (97.37) | 576 (94.10) | -3.3 (-5.5, -1.0) | 0.0066 | 585 (98.65) | 558 (96.04) | -2.6 (-4.4, -0.8) | 0.0059 |